Clinicalpharmacological study of 0.0015% DE-085 (tafluprost) ophthalmic solution in healthy adult male volunteers. -ocular blood flow measurements as efficacy endpoints-

Clinicalpharmacological study of 0.0015% DE-085 (tafluprost) ophthalmic solution in healthy adult male volunteers. -ocular blood flow measurements as efficacy endpoints- - Clinicalpharmacological study of 0.0015% DE-085 (tafluprost) ophthalmic solution.

Status

Active, not recruiting

Phases

Phase 1

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000000518

Enrollment

Registered

2006-11-13

Start date

2006-03-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Glaucoma

Interventions

0.0015% DE-085 (Tafluprost) ophthalmic solution One drop at a time, single administration in the right eye 0.01% bunazosin hydrochloride ophthalmic solution One drop at a time, single administra

Eligibility

Sex/Gender

Male

Inclusion criteria

Inclusion criteria: 1) Age of 20 to 35 years old; 2) Gender: male; 3) Subject who can complete the prescribed course and comply with appropriate instructions.

Exclusion criteria

Exclusion criteria: 1) Any clinically abnormal findings at screening examinations.

Design outcomes

Primary

Measure	Time frame
(1) Peripapillary retinal and neuroretinal rim hemodynamics (2) Peripapillary retinal artery hemodynamics	—

Countries

Japan

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026